Meeting
2021 ASCO Annual Meeting
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
Presenter
Beverly Moy, FASCO, MD, MPH
Massachusetts General Hospital Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00878709
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 540)
DOI
10.1200/JCO.2021.39.15_suppl.540
Abstract #
540
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2015 Breast Cancer Symposium
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.
Speaker: Arlene Chan, MD
Videos & Slides
2024 ASCO Annual Meeting
Intensive Therapy or Not? What to Offer Younger Patients With Acute Myeloid Leukemia
Speaker: Christine McMahon, MD
Videos & Slides
2024 ASCO Annual Meeting
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.
Speaker: Jeanne Tie, MD, FRACP, MBChB
Speaker: Felicia Knaul